Showing 5541-5550 of 8551 results for "".
- Evelo's AD Candidate Meets Phase 1b Endpointshttps://practicaldermatology.com/news/evelos-ad-candidate-meets-phase-1b-endpoints/2460631/Evelo Biosciences, Inc.’s investigational atopic dermatitis treatment EDP1815 was well tolerated with no serious adverse events in a phase 1b clinical trial. According to the company, the oral drug candidate studied in 23 evaluable subjects with
- UCB, Stanford Medicine Partner to Seek New Ways to Treat HS, Other Diseaseshttps://practicaldermatology.com/news/ucb-stanford-medical-partner-to-seek-new-ways-to-treat-hs-other-diseases/2460613/UCB and
- More Positive Phase 3 Data for Pfizer's Abrocitinib in ADhttps://practicaldermatology.com/news/more-positive-phase-3-data-for-pfizers-abrocitinib-in-ad/2460607/Positive top-line results from the phase 3 JADE REGIMEN study offer additional data in support of Pfizer's investigational oral once-daily Janus kinase 1 (JAK1) inhibitor for atopic dermatitis (AD). The 52-week study looked at patients 12 and older wi
- EADV Congress Update: Insights on Psoriasis, AD, UV Protection, COVID-19, and Morehttps://practicaldermatology.com/news/eadv-congress-update-insights-on-psoriasis-ad-uv-protection-covid-19-and-more/2460588/From updates on investigational treatments for dermatologic diseases to emerging healthcare trends, data from the 29th EADV Congress, EADV Virtual suggest new directions in patient care. Psoriasis: Results from the phas
- Connect Biopharma to Present Additional Positive Results from the Phase 1b Study of CBP-201 for Patients with Moderate-to-Severe AD at EADV Virtual Meetinghttps://practicaldermatology.com/news/connect-biopharma-to-present-additional-positive-results-from-the-phase-1b-study-of-cbp-201-for-patients-with-moderate-to-severe-ad-at-eadv-virtual-meeting/2460574/Connect Biopharma is slated to present the full results from the Phase 1b study of CPB-201, a novel IL-4R&alpha
- Coping with COVID: Most Psoriasis Patients Taking Immunosuppressants Survive COVID-19https://practicaldermatology.com/news/coping-with-covid-most-pso-patients-taking-immunosuppressants-survive-covid-19/2460573/Patients with psoriasis who are taking drugs that affect their immune system have high rates of survival from COVID-19, according to the first findings from a global registry of psoriasis and COVID-19 patients. The initial findings from the PsoProtect registry, which appear in the
- Industry Responds to COVID-19: TrueHero Face Shieldshttps://practicaldermatology.com/news/truehero-face-shields-offer-reusable-medical-grade-protection/2460572/Responding to the need for PPE across the US, Jamestown Plastics, has pivoted production to manufacture face shields to protect from COVID-19. The TrueHero Extreme Coverage Shield is suitable for medical use, including in dermatology and aesthetic practices.
- Eczema Missing Link Found: Researchers ID Protein that Triggers AD by Bacteriahttps://practicaldermatology.com/news/eczema-missing-link-found-researchers-id-protein-that-triggers-ad-by-bacteria/2460567/Second immunoglobulin-binding protein (Sbi) is a unique trigger of eczema by Staphylococcus aureus, according to research in the Journal of Allergy and Clinical Immunology. Sbi induces rapid release of Interleukin-33, a key component of the immune response in childhood ecz
- NEA Launches Free App To Help Those With Eczema Better Manage Conditionhttps://practicaldermatology.com/news/nea-launches-free-app-to-help-those-with-eczema-better-manage-condition/2460560/The
- Foreo Rolls Out Bear and Bear Mini with Help from TikTok Starshttps://practicaldermatology.com/news/foreo-rolls-out-bear-and-bear-mini-withhelp-from-tiktok-stars/2460537/